Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
出版年份 2023 全文链接
标题
Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
作者
关键词
-
出版物
Journal of Translational Medicine
Volume 21, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-01-09
DOI
10.1186/s12967-022-03848-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Organoid Cultures Derived From Patients With Papillary Thyroid Cancer
- (2021) Dong Chen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Characterizing dedifferentiation of thyroid cancer by integrated analysis
- (2021) Han Luo et al. Science Advances
- TERTpromoter mutation determines apoptotic and therapeutic responses ofBRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel
- (2020) Jie Tan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Understanding the ever-changing incidence of thyroid cancer
- (2020) Cari M. Kitahara et al. Nature Reviews Endocrinology
- An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity
- (2019) Oded Kopper et al. NATURE MEDICINE
- Cancer modeling meets human organoid technology
- (2019) David Tuveson et al. SCIENCE
- Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening
- (2019) Matteo Boretto et al. NATURE CELL BIOLOGY
- Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer
- (2019) Ye Yao et al. Cell Stem Cell
- A rectal cancer organoid platform to study individual responses to chemoradiation
- (2019) Karuna Ganesh et al. NATURE MEDICINE
- Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients
- (2019) Salo N. Ooft et al. Science Translational Medicine
- Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
- (2019) Minsuh Kim et al. Nature Communications
- Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro
- (2019) Timothy M. Ullmann et al. SURGERY
- OUP accepted manuscript
- (2018) BIOINFORMATICS
- A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity
- (2018) Norman Sachs et al. CELL
- Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
- (2018) Suk Hyung Lee et al. CELL
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
- (2018) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of receptor tyrosine kinase activation in cancer
- (2018) Zhenfang Du et al. Molecular Cancer
- Strelka2: fast and accurate calling of germline and somatic variants
- (2018) Sangtae Kim et al. NATURE METHODS
- BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines
- (2018) Ricarda Herr et al. ONCOGENE
- Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
- (2018) Georgios Vlachogiannis et al. SCIENCE
- Organoid profiling identifies common responders to chemotherapy in pancreatic cancer
- (2018) Hervé Tiriac et al. Cancer Discovery
- Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics
- (2018) Xiaodun Li et al. Nature Communications
- A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening
- (2018) Helen H.N. Yan et al. Cell Stem Cell
- Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
- (2017) Laura Broutier et al. NATURE MEDICINE
- HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
- (2017) Lingxiao Cheng et al. Oncotarget
- Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation
- (2017) Angelica Schmidt et al. Archives of Endocrinology Metabolism
- Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
- (2016) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
- (2016) Marcia S Brose et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
- (2015) Marc van de Wetering et al. CELL
- Organoid Models of Human and Mouse Ductal Pancreatic Cancer
- (2015) Sylvia F. Boj et al. CELL
- Intratumor heterogeneity and clonal evolution in an aggressive papillary thyroid cancer and matched metastases
- (2015) S. Le Pennec et al. ENDOCRINE-RELATED CANCER
- Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E-Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience
- (2015) Ramona Dadu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
- (2015) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer
- (2015) Mingzhao Xing et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell– and patient-derived tumor organoids
- (2015) Ling Huang et al. NATURE MEDICINE
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAF Inhibitor Dabrafenib in Patients with MetastaticBRAF-Mutant Thyroid Cancer
- (2015) Gerald S. Falchook et al. THYROID
- Organoid Cultures Derived from Patients with Advanced Prostate Cancer
- (2014) Dong Gao et al. CELL
- High-SensitivityBRAFMutation Analysis:BRAFV600E Is Acquired Early During Tumor Development but Is Heterogeneously Distributed in a Subset of Papillary Thyroid Carcinomas
- (2014) Dario de Biase et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
- (2014) M. Hidalgo et al. Cancer Discovery
- Definition and management of radioactive iodine-refractory differentiated thyroid cancer
- (2014) Martin Schlumberger et al. Lancet Diabetes & Endocrinology
- Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAFV600E Mutation
- (2013) Kevin B. Kim et al. THYROID
- Evaluating cell lines as tumour models by comparison of genomic profiles
- (2013) Silvia Domcke et al. Nature Communications
- Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF -Mutant Thyroid Carcinomas
- (2013) Cristina Montero-Conde et al. Cancer Discovery
- Tyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance
- (2012) Alexander Levitzki Annual Review of Pharmacology and Toxicology
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Patient-derived tumour xenografts as models for oncology drug development
- (2012) John J. Tentler et al. Nature Reviews Clinical Oncology
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data
- (2011) Valentina Boeva et al. BIOINFORMATICS
- Long-term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium
- (2011) Toshiro Sato et al. GASTROENTEROLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fast and accurate long-read alignment with Burrows–Wheeler transform
- (2010) Heng Li et al. BIOINFORMATICS
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
- (2010) A. McKenna et al. GENOME RESEARCH
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer
- (2010) Jiayi Wang et al. NUCLEIC ACIDS RESEARCH
- Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors inBRAFMutant Thyroid Carcinoma Cells
- (2009) Paolo Salerno et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started